Hemophilia A treatment Market – Segmented By Type, Application, Technology and Geography – Growth, Trends & Forecast (2016 – 2022)

22/ago/2019 11:21:46 MonicaK Contatta l'autore

Questo comunicato è stato pubblicato più di 30 giorni fa. Le informazioni su questa pagina potrebbero non essere attendibili.

New York, NY 22 August 2019: Hemophilia A patients have begun to shift from short acting to EHL factors and from on demand therapies to prophylactics. The increasing prevalent population of Hemophilia A and the rise in demand of the prophylactics treatments in developed markets will have a great impact on this market.

 

According to the US Centers for Disease Control and Prevention, hemophilia A occurs in 1 in 5,000 live male births. Hemophilia A is about four times as common as hemophilia B.  The number of people with hemophilia in the United States is estimated to be about 20,000 individuals. Approximately 75% of people with hemophilia around the world still receive inadequate treatment or have no access to treatment.

 

Get sample copy of this report @ https://www.polarismarketresearch.com/industry-analysis/hemophilia-a-treatment-market/request-for-sample

 

As of January 2018, there are over 450 reported Clinical Trials for Hemophilia A with 50+ trials currently actively ongoing. Out of all the trials, 120+ studies are funded by the pharmaceutical companies alone. The major players with drugs in Phase III are Alnylam Pharmaceuticals, Sanofi (Genzyme), BioMarin Pharmaceutical, Hoffmann-La Roche, Sinocelltech Ltd., Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, Octapharma, LFB USA, Inc., Novo Nordisk A/S, Pfizer and others.

 

Polaris Market Research expects that with the expected launch of the promising treatments, the market is expected to expand in Hemophilia A segment. The United States dominates the Hemophilia A treatment market followed by Europe 5 and Japan. The prophylaxis segments are predicted to be the fastest growing segment whereas the on-demand therapy segment is expected to contribute close to ~50% to the market during the forecast period. With the increase in the R&D investments and rising drug innovations in this field, the market is expected to significantly expand in the next five years.

 

Browse for full research summary: https://www.polarismarketresearch.com/industry-analysis/hemophilia-a-treatment-market

 

RNA based therapeutics and curative gene therapies are rapidly progressing through clinical development and are seen as an attractive segment of this market.

 

Market Size & Forecast of Hemophilia A Treatment (2016-2022)

  • Market Forecast by Disease Care
    • Prophylaxis-Market Forecast (2016-2022)
    • On-demand therapy-Market Forecast (2016-2022)
    • Inhibitor therapy- Market Forecast (2016-2022)
  • Market Forecast by G7 Countries (2016-2022)
    • United States- Market Forecast (2016-2022)
    • Germany- Market Forecast (2016-2022)
    • France-Market Forecast (2016-2022)
    • Italy- Market Forecast (2016-2022)
    • Spain- Market Forecast (2016-2022)
    • United Kingdom- Market Forecast (2016-2022)
    • Japan- Market Forecast (2016-2022)

Avail discount on this report @ https://www.polarismarketresearch.com/industry-analysis/hemophilia-a-treatment-market/request-for-discount-pricing

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. We provide unmatched quality of offerings to our clients present globally. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world.

 

Contact us-

 

Mr. Rohit

Corporate Sales, USA

Polaris Market Research

Phone: 1-646-568-9980

Email: sales@polarismarketresearch.com 

Web: www.polarismarketresearch.com

 

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl